Abstract:Poly (ADP-ribose) polymerases (PARP) are a family of nuclear protein enzymes involved in the DNA damage response. The role of PARP-1 in base excisional repair has been extensively characterized. More recent in vitro studies additionally implicate a role for PARP-1 in facilitating homologous recombination and nonhomologous end-joining. The more faithful process of homologous recombination repair of double-stranded DNA breaks involves localization of BRCA-1 and BRCA-2 to sites of DNA damage, resection of the double-stranded break, and gap-filling DNA synthesis using the homologous sister chromatid as a template. Simultaneous dysfunction of both DNA repair pathways decreases the ability of cells to compensate, and forms the basis for the concept of synthetic lethality. Treatment strategies, thus far, have focused on two main principles: (i) exploitation of the concept of synthetic lethality in homologous recombination-deficient tumors, primarily in breast and ovarian cancer patients with BRCA mutation, and (ii) as radiosensitizers and chemosensitizers. BRCA deficiency accounts for only a fraction of dysfunction in homologous recombination repair. Epigenetic alterations of BRCA function and defects within the Fanconi anemia pathway also result in defective DNA repair. Rational therapeutic combinations exploiting alternate mechanisms of defective DNA repair, abrogation of cell-cycle checkpoints, and additional functions of PARP-1 present novel opportunities for further clinical development of PARP inhibitors. On the basis of the results of clinical studies of PARP inhibitors thus far, it is imperative that future development of PARP inhibitors take a more refined approach, identifying the unique subset of patients that would most benefit from these agents, determining the optimal time for use, and identifying the optimal combination partner in any particular setting.

Ionic conducting lanthanide oxides.

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.

Targeting DNA damage response pathways in cancer

Custom-made cast titanium implants produced with CAD/CAM for the reconstruction of cranium defects.

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Abstract IA010: Latest developments in targeting the DNA damage response in the clinic

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Abstract IA017: Drugging the DNA damage response (DDR) in the Clinic: Going beyond the approved PARP inhibitors

Targeting the DNA damage response in hematological malignancies

Recent Progress in DNA Damage Response-Targeting PROTAC Degraders

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity

DNA Damage Response Inhibitors: an Avenue for TNBC Treatment

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

Molecular Pathways: Targeting PARP in Cancer Treatment

Development and therapeutic potential of DNA-dependent protein kinase inhibitors

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer